explore -WSS

explore

author：comprehensive 2025-09-06 05:03:07 - browse：88

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Dems pitch expanding Medicare power to negotiate drug prices

leisure time

WSS

How doctors’ personal politics affect patients

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Former New York Mayor de Blasio and wife announce separation, but not divorce

STAT Report: Patient voices and perspectives

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Pope Francis asks Church to identify 21st

focus

explore

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Malaria cases in Florida and Texas: Here’s what you need to know

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Tori Bowie and the unacceptable rates of Black maternal death

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Tori Bowie and the unacceptable rates of Black maternal death

New Alzheimer's drugs heat up race for early detection blood tests

United colonoscopy coverage change 'may cost lives,' doctors say

Truvian presents data for its desktop blood

knowledge

Search called off for baby washed away in Pennsylvania flash flood

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

How doctors’ personal politics affect patients

The haunting brain science of long Covid

The haunting brain science of long Covid

5 shark bites reported on Long Island as officials deploy surveillance drones

focus

explore

leisure time

leisure time